Key Points
- CEO Marc Casper sold 275 Thermo Fisher shares at an average price of $627.05, generating $172,438.75. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his stake by 0.22%.
- Thermo Fisher recently exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue rising 10.5% year over year. The company maintained fiscal 2026 EPS guidance of $24.93–$25.33.
- Analysts hold a consensus “Moderate Buy” rating with an average price target of $619.41, while the company declared a quarterly dividend of $0.47 per share, yielding approximately 0.3% annually.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc Casper sold 275 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thermo Fisher Scientific Stock Performance
NYSE TMO opened at $634.48 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The company has a fifty day moving average price of $552.22 and a 200-day moving average price of $510.70. The firm has a market cap of $234.60 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.
Wall Street Analysts Forecast Growth
TMO has been the subject of several recent research reports. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Piper Sandler lifted their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $619.41.
Get Our Latest Research Report on Thermo Fisher Scientific
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Legacy Wealth Managment LLC ID raised its holdings in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $25,000. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth about $26,000. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
